Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of SBRT Plus Chemotherapy for NSCLC
NCT02319889Phase 1Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Number of participants with prohibitive dose limiting toxicities at 1 year. Started Feb 2016; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02319889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319889.